|
|
|
|
 |
| August 11, 2011 | ISSUE NUMBER 212 VOL 8 |
Marketing
NICE Ads Deserve a Double Take
Industry may disagree with much of the criteria and methodology NICE uses to make decisions about which products the UK’s National Health Services will reimburse, but that doesn’t stop some companies from touting a NICE recommendation in their marketing materials ...Read more
Economy
How Will Pharma Fill the Financing Gap?
The confluence of a public deficit crisis and the internal industry revenue gap created by genericization, a slower uptake in the market for new drugs, lackluster pipelines, and a risk-averse FDA means one thing: Big Pharma must choose its battles wisely ...Read More
Commentary
Financing the Path To Better Health: Five Critical Themes
The next five years provides a window of opportunity for Big Pharma to apply its deep exposure to healthcare practices around the world to help that business model thrive in these emerging markets—where the global future is being set today
...Read More
Technology
What Does Google+ Mean for Pharma?
The Google+ beta was released in a field trial in late June, and early indications are that the service incorporates features that might get pharma past some of the pitfalls associated with today's dominant platforms ...Read more
|
|
|
 // Tranzyme Pharma (Research Triangle Park, NC) announced that David Moore joined the company as Vice President, Commercial Operations. // Acucela (Seattle) appointed Michelle Carpenter, J.D., RAC, as Senior Vice President, Regulatory Affairs & Development Operations. //
inVentiv Health (Burlington, Mass.) appointed Mark Dmytruk as President of inVentiv Health Patient Outcomes.
//
Global CRO Ockham (Cary, NC) announced the appointment of Meghann Smith as Senior Director, Global Therapeutic Strategic Development, within the Ockham
CRO division. |
|
|
|
|
|
 |
|
| |
|
 |
|
 |
| How should FDA implement its US biosimilar pathway plan? |
|
|
|
|
You
are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To
ensure delivery to your Inbox, please add us to your
address book. If you need help doing this, click
here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
